ClinicalTrials.gg
RecruitingNCT07119177LEGENDUpdated Aug 12, 2025

Long-term Evaluation of Gestational Endocrine & Metabolic Dynamics

An observational study in Gestational Diabetes Mellitus (GDM) and Non-communicable Chronic Diseases, sponsored by Yang ZHANG. Recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by Yang ZHANG · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
800
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 68 studies in Diabetes, Gestational with a site in China — 19 open to participants now, 23 under way, none of them phase 3. Diabetes, Gestational · China.

Planned enrollment
17th of 29
800 · median 1,122
Started
2025
with 1 other
Observational
29 of 68
12 open now
Primary completion
2026-12
later than 15 of 22 live
Registered
63rd of 68
by date

Among the 68 studies in Diabetes, Gestational with a site in China, this one is the 17th largest by planned enrollment of the 29 observational ones that give a count, is one of 2 that started in 2025, is one of 29 observational ones, reaches primary completion later than 15 of the 22 other live ones, and was the 63rd registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

19 of the 68 studies in Diabetes, Gestational with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Diabetes, Gestational with a site in China, or all of them as a file.
02

Study summary

Gestational diabetes mellitus (GDM) is the most common complication and metabolic disorder during pregnancy, with clear risks to both the mother and fetus. In recent years, the long-term chronic diseases and poor prognosis in GDM women after delivery, as well as the risk of obesity and metabolic disorders in their offspring, have become key research topics. However, due to the long duration of GDM's impact on both the mother and offspring and its involvement in multiple disciplines, high-quality cohort studies are scarce. As a result, there is no definitive conclusion regarding the high-risk factors, natural progression, key mediators, timing of interventions, and targets for GDM's long-term effects on mothers and their offspring. This project intends to initiate a prospective follow-up study, establish a specialized cohort for the long-term effects of GDM on both mothers and their offspring, and complete the characterization of the natural course of non-communicable chronic diseases (NCDs) in GDM women and their offspring. The study will also explore high-risk and mediator factors, and develop predictive models. The goal is to provide education, postpartum follow-up, monitoring, and possibly initiate primary prevention for GDM women to reduce the long-term NCD risks, ultimately improving their life expectancy and providing a theoretical basis for intervention.

Inclusion Criteria:

  1. Adult patients (≥18 years old) who registered for antenatal care and delivered at Peking University Firest Hospital's obstetrics department between 2007 and 2016.
  2. Diagnosed with gestational diabetes mellitus (GDM) during pregnancy via an oral glucose tolerance test (OGTT).
  3. Signed informed consent.

Exclusion Criteria:

  1. Lack of pregnancy-related obstetric follow-up records.
  2. Inability to cooperate with and complete subsequent scheduled follow-ups.
03

Conditions studied

  • Gestational Diabetes Mellitus (GDM)
  • Non-communicable Chronic Diseases

Keywords

  • Gestational Diabetes Mellitus
  • Long-term Impact
  • Non-communicable Chronic Diseases
  • Prospective Cohort
  • Predictive Model
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Gestational diabetes mellitus (GDM) patients who delivered at Peking University First Hospital between 2007 and 2016 will be identified through electronic medical record searches. We intend to enroll a total of 800 GDM patients meeting the above inclusion/exclusion criteria and their offspring.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥18 years old) who registered for antenatal care and delivered at Peking University Firest Hospital's obstetrics department between 2007 and 2016.
  • Diagnosed with gestational diabetes mellitus (GDM) during pregnancy via an oral glucose tolerance test (OGTT).
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Lack of pregnancy-related obstetric follow-up records.
  • Inability to cooperate with and complete subsequent scheduled follow-ups.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
800 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Prevalence of type 2 diabetes mellitus

    Subjects who meet either criterion 1 or 2 will be considered to have type 2 diabetes: 1. With classical symptoms of diabetes: if any one of the following is met: Random plasma glucose ≥ 11.1 mmol/L, or Fasting plasma glucose (FPG) ≥ 7.0 mmol/L, or 2-hour plasma glucose during an oral glucose tolerance test (OGTT) ≥ 11.1 mmol/L, or HbA1c (glycated hemoglobin) ≥ 6.5%. 2. Without classical symptoms of diabetes: either two glucose indicators measured at the same time point reaching or exceeding diagnostic thresholds, or Glucose indicators measured at two different time points reaching or exceeding diagnostic thresholds (excluding random plasma glucose).

    Time frame: At 8-17 years postpartum

  2. Prevalence of metabolic syndrome

    Individuals meeting 3 or more of the following 5 components will be considered to have metabolic syndrome: 1. Waist circumference ≥ 85 cm in women; 2. FPG ≥ 6.1 mmol/L and/or 2hPG ≥ 7.8 mmol/L, and/or previously diagnosed diabetes; 3. Blood pressure ≥ 130/85 mmHg, and/or previously diagnosed hypertension and treated; 4. Fasting TG ≥ 1.7 mmol/L; 5. Fasting HDL-C \< 1.04 mmol/L.

    Time frame: At 8-17 years postpartum

  3. Prevalence of cardiovascular diseases

    The presence of any of the following items is considered indicative of cardiovascular disease: 1. Inquire about history(definitively diagnosed by a qualified physician) of cardiovascular diseases, including coronary heart disease, hypertension and arrhythmia. 2. Quantify coronary artery calcium score via non-contrast CT scan, \> 100 indicates elevated risk for coronary heart disease. 3. With Framingham Cardiovascular Risk Score calculated for non-diseased individuals(men ≥15 and women ≥18 are classified as high cardiovascular risk). 4. Perform an electrocardiogram for diagnose of arrhythmia. 5. ABI, TBI, and baPWV are utilized to assess arteriosclerosis in the extremities, ABI \< 0.9 or TBI \< 0.7 or baPWV \> 1400 cm/s is diagnostic of peripheral arterial disease. 6. Carotid ultrasonography is performed to assess carotid plaque.

    Time frame: At 8-17 years postpartum

  4. Prevalence of cognitive function

    Inquire about history of cognitive function(definitively diagnosed by a qualified physician).

    Time frame: At 8-17 years postpartum

  5. Prevalence of renal disease

    Subjects who meet criterion 1 or 2 will be considered to have renal disease: 1. Serum creatinine\>133μmol/L. 2. Urinary microalbumin/urinary creatinine\>30mg/g.

    Time frame: At 8-17 years postpartum

Secondary outcomes

  1. Prevalence of anxiety

    Assessed by standardized depression and anxiety scales \[Zung Self-rating Anxiety Scale(SAS)\]. Anxiety Severity Classification: Normal: \<50, Mild Anxiety: 50-59, Moderate Anxiety: 60-69, Severe Anxiety: ≥70

    Time frame: At 8-17 years postpartum

  2. Thyroid Function

    Assessed via measurement of thyroid hormone levels

    Time frame: At 8-17 years postpartum

  3. Bone Density

    Assessed via quantitative ultrasound (QUS) measurement of T-scores and Z-scores at the bilateral distal radius.

    Time frame: At 8-17 years postpartum

  4. Offspring Growth and Development

    Growth curve values persistently below the 3rd percentile (P3) or above the 97th percentile (P97), as defined by the \*China Height and Weight Percentile Curves for Children and Adolescents Aged 2-18 Years\* developed by the Growth and Development Research Laboratory, Capital Institute of Pediatrics, were considered indicative of abnormal growth

    Time frame: At 8-17 years old

  5. CAIDE Dementia Risk Score

    With CAIDE Dementia Risk Score calculated for individuals without history of cognitive function.

    Time frame: At 8-17 years postpartum

  6. N-acetyl-β-D-glucosaminidase (NAG)

    \>12U/L is considered early-stage renal tubule injury.

    Time frame: At 8-17 years postpartum

  7. Prevalence of depression

    Assessed by standardized depression and anxiety scales \[Zung Self-Rating Depression Scale(SDS)\]. Depression Severity Classification: Normal: \<53, Mild Depression: 53-62, Moderate Depression: 63-72, Severe Depression: ≥73

    Time frame: At 8-17 years postpartum

  8. Hyperuricemia

    Serum uric acid levels exceed 420 μmol/L.

    Time frame: At 8-17 years postpartum

  9. Hyperhomocysteinemia

    Serum homocysteine \>15 μmol/L

    Time frame: At 8-17 years postpartum

  10. Fatty liver disease

    Liver Transient Elastography (CAP) Fat Attenuation Grading: Normal: \<244 dB/m Mild Hepatic Steatosis: 244-269 dB/m Moderate Hepatic Steatosis: 269-296 dB/m Severe Hepatic Steatosis: \>296 dB/m

    Time frame: At 8-17 years postpartum

  11. Body fat percentage:

    18%-28% is considered normal.

    Time frame: At 8-17 years postpartum

  12. Kutcher Adolescent Depression Scale (11-item version, KADS-11)

    Range: 0-33; Higher scores indicate worse status. A total score ≥9 suggests a depressive state.

    Time frame: 11-17 years old

  13. Swanson, Nolan, and Pelham Rating Scale (SNAP-IV)

    Items 1-9 constitute the Attention Deficit subscale (range: 0-27, ≤13: Normal); Items 10-18 constitute the Hyperactivity-Impulsivity subscale (range: 0-27, ≤13: Normal); Items 19-26 constitute the Oppositional Defiant subscale: Abnormality is defined as ≥4 items scored as 2 or 3.

    Time frame: 10-18 years old

  14. Screen for Child Anxiety Related Emotional Disorders (SCARED)

    Range: 0-82; Higher scores indicate worse condition; a total score ≥25 suggests anxiety.

    Time frame: 10-18 years old

  15. Social Anxiety Scale for Children (SASC)

    Range: 0-20; Higher scores indicate worse condition; no standardized cutoff.

    Time frame: 10-18 years old

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The clinical information of the participants and the primary outcome data of the LEGEND study will be shared

Supporting information: Study protocol, Clinical study report

Time frame: IPD will be available half year after the last participants finished the study

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Of 142 non-industry observational studies under Diabetes, Gestational, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 21 months is below that.

Counting every sponsor, half of 144 studies reached it within 43 months; a quarter within 19 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2025
First posted
Aug 12, 2025
StartActual
Mar 29, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07119177
Lead sponsor
Yang ZHANG
Collaborators
National Institute of Health Data Science at Peking University
Responsible party
Yang ZHANG (Associated chief of the endocrinology department of peking university first hospital, Peking University First Hospital) — Sponsor-investigator
First posted
Aug 12, 2025
Start date
Mar 29, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 12, 2025

Study contacts

YANG ZHANG, Doctor
Contact
emilyzy14@sina.com
008601083575103

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion